Pet Drug Reports

Drugs by active ingredient › Clotrimazole + Gentamicin

Drug · combination of 2 active ingredients

Clotrimazole + Gentamicin: adverse event reports

All products with this ingredient combination · not in an FDA-approved animal drug

1,321reports naming this combination, 2004–20260.1% of all reports · about 61 a year
69reports, 12 months to March 2026122 in the 12 months before
36.2%classed serious, as reportedof 1,198 reports stating it
3.6%record death or euthanasia, as reported48 reports
95.5%of reports concern dogs0.1% of all dog reports

1,321 adverse event reports in FDA's database list a drug whose active ingredients are recorded as the combination clotrimazole and gentamicin. The earliest was received in October 2004, the latest in March 2026. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient combination across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 69 reports named it, down 43% from 122 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 61 reports a year and 0.1% of all 1,357,245 reports (0.1% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are temporary deafness (35.9%), pR-ear(s), lesion(s) (20.8%) and loss of hearing (18.1%). A report can list several signs, so shares add to more than 100%; 626 different terms appear across these reports. Temporary deafness appears in 35.9% of these reports, a larger share than in the pooled reports for every drug containing gentamicin (27%).

95.5% of reports concern dogs. Not every report describes illness: 15.1% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 36.2% were classed as serious, and 3.6% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog525 · peak 18
Apr 2021: 13May 2021: 14Jun 2021: 10Jul 2021: 6Aug 2021: 17Sep 2021: 9Oct 2021: 15Nov 2021: 18Dec 2021: 10Jan 2022: 9Feb 2022: 9Mar 2022: 7Apr 2022: 6May 2022: 5Jun 2022: 17Jul 2022: 6Aug 2022: 13Sep 2022: 11Oct 2022: 8Nov 2022: 10Dec 2022: 10Jan 2023: 10Feb 2023: 4Mar 2023: 14Apr 2023: 12May 2023: 9Jun 2023: 3Jul 2023: 13Aug 2023: 10Sep 2023: 14Oct 2023: 10Nov 2023: 10Dec 2023: 7Jan 2024: 6Feb 2024: 9Mar 2024: 5Apr 2024: 4May 2024: 11Jun 2024: 8Jul 2024: 7Aug 2024: 8Sep 2024: 9Oct 2024: 13Nov 2024: 12Dec 2024: 12Jan 2025: 12Feb 2025: 7Mar 2025: 7Apr 2025: 4May 2025: 5Jun 2025: 5Jul 2025: 5Aug 2025: 6Sep 2025: 5Oct 2025: 3Nov 2025: 8Dec 2025: 7Jan 2026: 3Feb 2026: 4Mar 2026: 12022202320242025
Cat20 · peak 3
Jun 2021: 1Oct 2021: 1Mar 2022: 1May 2022: 1Sep 2022: 1Nov 2022: 1Feb 2024: 1Aug 2024: 1Nov 2024: 1Dec 2024: 2Feb 2025: 1Mar 2025: 2Apr 2025: 3Jun 2025: 1Aug 2025: 1Nov 2025: 12022202320242025
Horse0 · peak 1
2022202320242025
Other20 · peak 4
Aug 2022: 1Jan 2023: 4Mar 2023: 1Nov 2023: 1Jan 2024: 1Jul 2024: 1Aug 2024: 3Jan 2025: 1Apr 2025: 1May 2025: 1Jun 2025: 1Aug 2025: 1Oct 2025: 1Nov 2025: 1Dec 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

01022032004: 120042006: 12007: 220072009: 12011: 5920112012: 542013: 4820132014: 392015: 3220152016: 272017: 4020172018: 482019: 14620192020: 2032021: 16920212022: 1162023: 12220232024: 1142025: 9120252026: 8

2026 covers reports received through March 2026 only.

Signs listed in reports

share of clotrimazole + gentamicin reports listing the termall drugs containing gentamicinall dog reports

  1. PR-ear(s), lesion(s)[legacy FDA term: lesions found in the ears]20.8%275
  2. Deafness8.3%110
  3. Emesis[vomiting]6%79
  4. Lethargy[unusually tired or inactive]6%79
  5. Lack of efficacy - NOS[the product did not have the expected effect]3.7%49
  6. Behavioural disorder NOS[behaviour change, type not specified]2.3%30
  7. Diarrhoea[diarrhea]2.3%30
  8. Anorexia[not eating]2.1%28
  9. Other abnormal test result NOS[abnormal laboratory result, type not specified]1.8%24
  10. Ear infection NOS[NOS: not otherwise specified]1.7%23
  11. Death by euthanasia[the animal was euthanized]1.6%21
  12. Ataxia[unsteady, uncoordinated movement]1.5%20
  13. Seizure NOS[seizure, type not specified]1.5%20
  14. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]1.3%17
  15. Death1.2%16
  16. Underdose[less than the labelled amount was given]1.2%16
  17. Ear pain1.1%15
  18. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]1.1%15

Top 30 of 626 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal28.5%377
Recovered with Sequela3.6%48
Ongoing33.7%445
Died1.7%23
Euthanized1.9%25
Outcome Unknown28.3%374

What kind of report it was

Safety issue81.9%1,082
Lack of expected effectiveness12.6%166
Both safety and lack of expected effectiveness2.6%34
Manufacturing or product defect2.9%38
Other0.1%1

Coloured bar: reports naming clotrimazole + gentamicin. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog95.5%1,261
Cat2.3%30
Human exposure0.2%3

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year3.4%45
1 to 3 years10.4%138
4 to 7 years15.7%208
8 to 11 years30.1%397
12 years and over28.8%380
Age not given11.6%153

Weight of the animal

Under 5 kg (11 lb)7.9%104
5 to 9.9 kg (11–22 lb)19.3%255
10 to 24.9 kg (22–55 lb)22%290
25 to 44.9 kg (55–99 lb)28.5%377
45 kg and over (99 lb+)2.8%37
Weight not given19.5%258

Route of administration stated in reports: auricular (otic) (793), topical (53), oral (10), hemodialysis (1), intraocular (1), ophthalmic (1).

In context

MeasureClotrimazole + GentamicinAll drugs containing gentamicinAll dog reportsAll reports
Reports1,3211,757985,6751,357,245
Share of that pool's reports naming this drug—75.2%0.1%0.1%
Classed serious, of reports stating it36.2%40.3%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports36.3605563.8
Filed as lack of expected effectiveness (wholly or partly)15.1%——23%
Top term, share of reportsTemporary deafness 35.9%27%0.1%—

The gentamicin pool is every report naming gentamicin alone or in any combination; this combination accounts for 75.2% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Active ingredientsReportsLatest 12 months
Betamethasone Valerate + Clotrimazole + Gentamicin Sulfate2,32912
Clotrimazole + Gentamicin Sulfate + Mometasone Furoate Monohydrate1,3278
Gentamicin22361
Clotrimazole + Gentamicin + Mometasone furoate1651
Clotrimazole + Gentamicin Sulfate + Mometasone furoate145121
Clotrimazole335
Clotrimazole + Gentamicin Sulfate222

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about clotrimazole + gentamicin reports

How many adverse event reports has FDA received for the combination clotrimazole and gentamicin?

1,321 reports record a drug with the combination clotrimazole and gentamicin as its active ingredients in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 69 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

temporary deafness (35.9%), pR-ear(s), lesion(s) (20.8%), loss of hearing (18.1%), deafness (8.3%) and emesis (6%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (95.5%), cat (2.3%) and human exposure (0.2%). Among single-breed animals the most frequent labels are Labrador Retriever, Yorkshire Terrier, Golden Retriever and German Shepherd Dog; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

69 reports in the 12 months to March 2026, down 43% from 122 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that clotrimazole + gentamicin harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of clotrimazole + gentamicin?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.